| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Executive Chairman
4 companies
Bisaro Paul serves as a Director at MYGN and has filed Form 4s across 4 companies. Across recent SEC filings that breaks down to 4 buys and 0 sells. Those positions are worth an estimated $3.2M at current prices.
The biggest single holding is ZTS (~$2.2M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 2,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | ZTS Zoetis Inc. | Director | Buy | 2,000 | $75.88 | $151,750.00 | +7.7% | - | - | |
| Aug 16, 2021 | TXMD Therapeuticsmd, Inc. | Director | Buy | 50,000 | $0.79 | $39,500.00 | +34.0% | -21.5% | -75.4% | |
| Jun 4, 2020 | TXMD Therapeuticsmd, Inc. | Director | Buy | 50,000 | $1.14 | $57,000.00 | New | - | - | |
| Mar 12, 2019 | AMRX Amneal Pharmaceuticals, Inc. | Executive Chairman | Buy | 17,000 | $11.97 | $203,490.00 | New | - | - |